CoChat

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides

Veltrop, Marcel, van Vliet, Laura, Hulsker, Margriet, Claassens, Jill, Brouwers, Conny, Breukel, Cor, van der Kaa, Jos, Linssen, Margot M., den Dunnen, Johan T., Verbeek, Sjef, Aartsma-Rus, Annemieke, van Putten, Maaike · 2018 · PLOS ONE
Cited by 64

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0193289

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 40

  1. JR Mendell, 2013, Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy, Muscle Nerve, 48, 21, 10.1002/mus.23810 · DOI · Paper page
  2. SJ Moat, 2013, Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK), Eur J Hum Genet, 21, 1049, 10.1038/ejhg.2012.301 · DOI · Paper page
  3. EP Hoffman, 1987, Dystrophin: the protein product of the Duchenne muscular dystrophy locus, Cell, 51, 919, 10.1016/0092-8674(87)90579-4 · DOI · Paper page
  4. Y Kharraz, 2014, Understanding the Process of Fibrosis in Duchenne Muscular Dystrophy, Biomed Res Int, 2014, 965631, 10.1155/2014/965631 · DOI · Paper page
  5. FA Marden, 2005, Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging, Skeletal Radiol, 34, 140, 10.1007/s00256-004-0825-3 · DOI
  6. L Zhou, 2010, Targeting fibrosis in Duchenne muscular dystrophy, J Neuropathol Exp Neurol, 69, 771, 10.1097/NEN.0b013e3181e9a34b · DOI · Paper page
  7. AP Monaco, 1988, An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus, Genomics, 2, 90, 10.1016/0888-7543(88)90113-9 · DOI · Paper page
  8. EP Hoffman, 1988, Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy, N Engl J Med, 318, 1363, 10.1056/NEJM198805263182104 · DOI · Paper page
  9. JC van den Bergen, 2013, Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy, J Neurol Neurosurg Psychiatry
  10. S Cirak, 2011, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study, Lancet, 378, 595, 10.1016/S0140-6736(11)60756-3 · DOI · Paper page
  11. NM Goemans, 2011, Systemic administration of PRO051 in Duchenne's muscular dystrophy, N Engl J Med, 364, 1513, 10.1056/NEJMoa1011367 · DOI · Paper page
  12. CL Bladen, 2015, The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations, Hum Mutat, 36, 395, 10.1002/humu.22758 · DOI · Paper page
  13. A Aartsma-Rus, 2009, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations, Hum Mutat, 30, 293, 10.1002/humu.20918 · DOI · Paper page
  14. A Aartsma-Rus, 2017, FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides, Nucleic Acid Ther, 27, 67, 10.1089/nat.2017.0665 · DOI · Paper page
  15. YY Syed, 2016, Eteplirsen: First Global Approval, Drugs, 76, 1699, 10.1007/s40265-016-0657-1 · DOI · Paper page
  16. SD Wilton, 1999, Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides, Neuromuscul Disord, 9, 330, 10.1016/S0960-8966(99)00010-3 · DOI · Paper page
  17. MG Dunckley, 1998, Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides, Hum Mol Genet, 7, 1083, 10.1093/hmg/7.7.1083 · DOI · Paper page
  18. PA 't Hoen, 2008, Generation and characterization of transgenic mice with the full-length human DMD gene, J Biol Chem, 283, 5899, 10.1074/jbc.M709410200 · DOI
  19. M Veltrop, 2013, Generation of embryonic stem cells and mice for duchenne research, PLoS Curr, 5
  20. T Cermak, 2011, Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting, Nucleic Acids Res, 39, e82, 10.1093/nar/gkr218 · DOI · Paper page
  21. EL Doyle, 2012, TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction, Nucleic Acids Res, 40, W117, 10.1093/nar/gks608 · DOI · Paper page
  22. AH Beggs, 1991, Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies, Am J Hum Genet, 49, 54
  23. P Spitali, 2010, Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy, Lab Invest, 90, 1396, 10.1038/labinvest.2010.98 · doi:10.1038/labinvest.2010.98
  24. A Aartsma-Rus, 2002, Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy, Neuromuscul Disord, 12, S71, 10.1016/S0960-8966(02)00086-X · DOI · Paper page
  25. JS Draper, 2007, Improved embryonic stem cell technologies, Handb Exp Pharmacol, 178, 107, 10.1007/978-3-540-35109-2_5 · DOI
  26. A Aartsma-Rus, 2014, Assessing functional performance in the mdx mouse model, J Vis Exp, 85
  27. AM Connolly, 2001, Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice, Neuromuscul Disord, 11, 703, 10.1016/S0960-8966(01)00232-2 · DOI
  28. M van Putten, 2012, Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains, Neuromuscul Disord, 22, 406, 10.1016/j.nmd.2011.10.011 · DOI
  29. M Hulsker, 2016, Accurate dystrophin quantification in mouse tissue; identification of new and evaluation of existing methods, Journal of Neuromuscular diseases, 1
  30. F Zhang, 2011, Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription, Nat Biotechnol, 29, 149, 10.1038/nbt.1775 · DOI · Paper page
  31. E Araki, 1997, Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy, Biochem Biophys Res Commun, 238, 492, 10.1006/bbrc.1997.7328 · DOI · Paper page
  32. Y Aoki, 2010, In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse, Mol Ther, 18, 1995, 10.1038/mt.2010.186 · DOI
  33. Y Echigoya, 2015, Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45–55 with a cocktail of vivo-morpholinos in mdx52 mice, Mol Ther Nucleic Acids, 4, e225, 10.1038/mtna.2014.76 · DOI
  34. Y Aoki, 2012, Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery, Proc Natl Acad Sci U S A, 109, 13763, 10.1073/pnas.1204638109 · DOI · Paper page
  35. HA Heemskerk, 2009, In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping, J Gene Med, 11, 257, 10.1002/jgm.1288 · DOI · Paper page
  36. B Wefers, 2016, Genome Editing in Mice Using TALE Nucleases, Methods Mol Biol, 1338, 229, 10.1007/978-1-4939-2932-0_17 · DOI
  37. M van Putten, 2012, The effects of low levels of dystrophin on mouse muscle function and pathology, PLoS One, 7, e31937, 10.1371/journal.pone.0031937 · DOI · Paper page
  38. M van Putten, 2013, Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice, FASEB J, 27, 2484, 10.1096/fj.12-224170 · DOI · Paper page
  39. JA Doudna, 2014, Genome editing. The new frontier of genome engineering with CRISPR-Cas9, Science, 346, 1258096, 10.1126/science.1258096 · DOI · Paper page
  40. CS Young, 2017, Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy, J Neuromuscul Dis, 4, 139, 10.3233/JND-170218 · DOI

Cited by

See all 64

Metadata

Authors
Veltrop, M., van Vliet, L., Hulsker, M., Claassens, J., Brouwers, C., Breukel, C., van der Kaa, J., Linssen, M. M., den Dunnen, J. T., Verbeek, S., Aartsma-Rus, A., & van Putten, M.
Venue
PLOS ONE
Published
2018-02-21
Volume
13
Issue
2
Pages
e0193289
ISSN
1932-6203
Cited by
64
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. https://app.cochat.ai/papers/10.1371/journal.pone.0193289
The paper
Veltrop, M., van Vliet, L., Hulsker, M., Claassens, J., Brouwers, C., Breukel, C., van der Kaa, J., Linssen, M. M., den Dunnen, J. T., Verbeek, S., Aartsma-Rus, A., & van Putten, M. (2018). A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. PLOS ONE. https://doi.org/10.1371/journal.pone.0193289

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.